Maria Robles
CEO & President
Maria Robles is the visionary President and CEO of Robles BioCeutics, a regenerative dermatology company dedicated to advancing skin health and rejuvenation. With a strong background in public health and economics, Maria brings a unique perspective to the biotech space, leveraging her expertise in product development and leadership.
Under her guidance, Robles BioCeutics has focused on creating innovative solutions in skin care, including the company's flagship product, Glowselle™. This powerful anti-aging skin cream harnesses the science of stem cell-derived growth factors and exosomes to stimulate natural regeneration, setting a new standard in skin care.
Maria’s passion for helping others maintain vitality, confidence, and overall wellness fuels her mission to deliver cutting-edge, stem cell-powered skin care solutions that truly make a difference.
Dr. Jorge Genovese, MD, PhD
Chief Scientific Officer
Dr. Jorge Genovese is an accomplished physician and scientist who earned both his M.D. and Ph.D. from Buenos Aires University. With a career spanning decades, he has made significant contributions to regenerative medicine and tissue engineering. As a faculty member of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh, Dr. Genovese led groundbreaking research as the Principal Investigator at the Center for Cardiac Cell Therapy and the Cardiac and Molecular Biology Laboratory. His expertise then took him to the University of Utah, where he served as Director of the Cardiac Regenerative Medicine Laboratory within the Cardiac Surgery Division.
Dr. Genovese's reputation as an innovative thinker in his field extended internationally, and he was invited to serve as a Cardiac Surgery Professor at Campus Biomedico University in Rome. He has also played a pivotal role in the Tissue Engineering International & Regenerative Medicine Society (TERMIS), chairing numerous committees and serving as Vice President. His dedication to advancing the field is reflected in his editorial contributions as Editor of the Journal of Stem Cells, Associate Editor of the Frontiers in Stem Cells Journal, and as a member of the Editorial Committee for the World Journal of Stem Cells.
In addition to his scientific and clinical accomplishments, Dr. Genovese has held influential leadership roles, including President of Hearten Biotech and Vice President of Bioelectric Research & Development at BioLeonhardt. He is also a member of the North American Veterinary Regenerative Medicine Association, further highlighting his multidisciplinary approach to innovation.
As a pioneer of tissue engineering in Latin America, Dr. Genovese was the first in the region to generate keratinocyte cultures in 1985. His trailblazing work continued with the development of an organotypic dermo-epidermic device in 1998, followed by a genetically modified dermo-epidermic device in 2002. These accomplishments, along with many other advances in tissue engineering, have solidified his legacy as a leader in the field.
Dr. Genovese’s innovative spirit extends to bioelectric stimulation, where he has co-invented numerous patents with Howard Leonhardt for organ regeneration and healing. His work has been instrumental in pushing the boundaries of what is possible in regenerative medicine, offering transformative solutions for both patients and practitioners. A comprehensive list of his patents is available here.
Dr. Joseph Ellis, DPM, CFP®, EA
Chief Financial Officer
Dr. Joseph Ellis is a distinguished serial entrepreneur with a rare combination of expertise in the medical and financial domains. His multifaceted career reflects a passion for advancing skin health and aging science through innovative dermatological solutions.
Dr. Ellis earned his Bachelor of Science and Doctor of Podiatric Medicine degrees from Samuel Merritt College. While there, he published his first scientific paper, “Tri-Plane Analyzer, Electronic in Motion,” in the prestigious Journal of the American Podiatry Association. This early work established a foundation for a career focused on improving health outcomes through clinical practice and technological innovation.
Leveraging his medical knowledge, Dr. Ellis patented a groundbreaking device for ASICS, a leading athletic shoe company. This device, now an industry standard in running and athletic footwear, demonstrates his commitment to enhancing athletic performance and preventing injuries through scientific advancements.
In addition to his medical achievements, Dr. Ellis holds the Certified Financial Planner™ designation, recognized as a gold standard for professionals advising on personal and business finances. To further assist clients in navigating complex tax regulations, he earned the Enrolled Agent (EA) credential from the IRS—the highest designation awarded by the agency. This accomplishment reflects his dedication to empowering clients to achieve financial success.
As a thought leader, Dr. Ellis has delivered keynote speeches on finance and medicine at national and international conferences. He is the author of two books and over 100 articles and vignettes, sharing his insights with a wide audience. His contributions to the field were recognized in 2016 when a readers’ poll by the San Diego Union-Tribune named him one of San Diego’s top financial advisors.
Over his career, Dr. Ellis has successfully founded and managed multiple ventures, including a multi-million-dollar company later acquired by a public entity. He is currently based in San Diego, where he is focused on authoring a book to empower individuals navigating the financial complexities of divorce.
Dr. Ellis is also a dedicated community advocate. Through his involvement with the Financial Futures Foundation, a non-profit organization committed to increasing financial literacy, he champions education and empowerment. His work reflects a lifelong belief in the transformative power of knowledge in both financial and medical spheres.
Dr. Feng Lin, MD, PhD
Dr. Feng Lin brings 21 years of expertise in immunotherapy and cell therapy, with a career distinguished by leadership roles in new product development and commercial functions at some of the biotech industry’s most prominent companies. His work has been instrumental in advancing antibody drugs and immune cell therapies from preclinical stages to clinical application, reflecting a deep commitment to innovation in therapeutic interventions.
Dr. Lin's academic journey began at Central South University Xiang-Ya School of Medicine in Changsha, China, where he earned a Ph.D. in Hematology and Physiology. He also holds an M.Sc. in Biochemistry and Molecular Biology and an M.D. in Medicine, providing a robust foundation for his contributions to biomedical research.
Throughout his career, Dr. Lin has demonstrated exceptional leadership, guiding diverse teams in the development of groundbreaking therapies. His work spans the forefront of personalized medicine, with a focus on addressing critical health challenges such as brain cancer, COVID-19, and traumatic brain injury.
Dr. Lin is also a prolific author, contributing to numerous high-impact publications that advance the understanding of immunotherapy, stem cell applications, and personalized medicine. Among his most recent works is a groundbreaking study on mRNA vaccines for brain cancer, published in the Journal of Translational Medicine (2023). Other notable contributions include investigations into mesenchymal stem cells as a treatment for COVID-19-related acute respiratory distress syndrome, glioblastoma therapies, and the role of cerebrospinal fluid in neurologic disorders.
With a career dedicated to pushing the boundaries of science and innovation, Dr. Lin continues to shape the future of healthcare through his research, leadership, and unwavering commitment to improving patient outcomes.
Dr. Navneet Boddu, MD
Dr. Navneet Boddu is a highly accomplished specialist in regenerative medicine with over 25 years of experience in interventional pain management. He is board-certified in Pain Medicine and Anesthesiology and holds additional expertise in Perioperative Transesophageal Echocardiography.
Dr. Boddu is the founder and CEO of Advanced Pain and Regenerative Specialists, where he provides personalized treatments for spine and joint disorders using cutting-edge technology and evidence-based cellular therapies. His innovative approach leverages the body’s natural healing potential through autologous bone marrow stem cells, platelet-rich plasma (PRP), Micro Fragmented Adipose Tissue (MFAT), and other biologics to regenerate and heal joints, tendons, ligaments, and spine conditions.
Recognized multiple times as a Top Doctor in Pain Medicine and Anesthesiology in San Diego County, Dr. Boddu has also made significant contributions to the field through research and leadership. His achievements include:
Contributing author to chapters in the Atlas of Interventional Orthopedics Procedures and regenerative medicine textbooks.
Conducting FDA-authorized umbilical cord stem cell treatments for severe COVID-19 patients.
Dr. Boddu currently serves as an anesthesiologist at Scripps Memorial Medical Center in Encinitas and sits on the scientific board of Therapeutic Solutions International, Inc., a biotech company specializing in stem cell, exosome, and immunotherapy technologies. His leadership experience includes serving as chairman of the Anesthesiology Department at TriCity Medical Center (2015–2017) and Providence Mission Hospital Laguna Beach.
Dr. Boddu’s patient care philosophy is rooted in his belief in the power of regenerative medicine:
"My practice focuses on treating joint and spine disorders using a patient’s own cells, which are a powerhouse of healing and regenerative properties."
Beyond his professional pursuits, Dr. Boddu enjoys surfing and hiking, embracing an active and balanced lifestyle.
Howard Leonhardt, Inventor, Serial Entrepreneur
Howard Leonhardt is a prolific inventor and serial entrepreneur with 38 issued U.S. patents and over 20 pending, covering more than 700 patent claims across diverse fields. He was the lead inventor and developer of the world’s leading stent graft system for aortic aneurysm repair and one of the first percutaneous heart valve systems. Leonhardt also pioneered one of the earliest stem cell delivery systems for internal organs and has dozens of patents related to organ regeneration, healthspan longevity, and medical aesthetics.
His groundbreaking work includes over 100 patent claims in medical aesthetics and issued patents for bioelectric and biologics-based cancer treatments. Additionally, he holds major patents for bioelectric control of high blood pressure, inflammation, and diabetes. In 2001, Leonhardt’s team performed the first non-surgical muscle stem cell repair of a human heart, publishing results from Pilot, Phase I, Phase II, and Phase II/III trials. He is currently developing a “womb for adults,” a whole-body regeneration chamber with multiple issued patents.
Leonhardt’s innovations have treated over 600,000 patients and generate nearly $2 billion in annual revenue today. His extensive educational background includes studies at Anoka Technical College, the University of Minnesota, Anoka-Ramsey College, and UCLA Extension. He holds an honorary Doctorate in Biomedical Engineering from the University of Northern California and is an honorary alumnus of the University of Florida and Florida International University. In 2004, he was named Florida Entrepreneur of the Year.
As the Executive Chairman & CEO of Leonhardt Ventures LLC (founded in 1982), Lionheart Health, Inc., BioLeonhardt, CancerCell, SkinStim, CerebraCell, Valvublator, Inc., and Leonhardt’s Launchpads, he oversees over 30 startups. He also serves as Executive Chairman of OrthodontiCell, Inc., focused on accelerated teeth straightening.
Beyond his contributions to healthcare, Leonhardt is a passionate winemaker and owner of Leonhardt Vineyards, producing award-winning wines since 1999. He has owned two indoor football teams, the Miami Morays and the Florida Frenzy, as well as the Wine Country Baseball League with 12 teams. Additionally, he is a co-owner of Lucille’s American Café.
Maxim Wheatley, Entrepreneur, Startup Executive
Maxim Wheatley, Founder and CEO of JetPatient, combines a strong foundation in neuroscience and psychology from Georgetown University with a dynamic entrepreneurial spirit. Initially pursuing medical school, Maxim conducted NIH-backed neuroscience research on Autism and ADHD before shifting his focus to healthcare innovation and technology.
His career began at a seed-stage venture fund and startup accelerator, setting the stage for his role as the technical co-founder and Chief Product Officer of LifeFuels, a health and wellness company. Under his leadership, LifeFuels achieved significant success, culminating in the sale of his stake to Keurig Dr. Pepper (NYSE: KDP).
Maxim went on to refine his leadership skills at TTEC, where he managed a national team overseeing more than $250 million in P&L. He secured the largest deal in company history—a $127 million contract with FEMA. Later, as the first employee at a machine learning company, he played a key role in scaling the business from inception to over 100 employees and seven figures in ARR, helping raise over $27 million from top-tier venture capital firms.
With over a dozen patents and extensive experience advising successful HealthTech and FinTech startups, Maxim is a recognized leader in the industry. His expertise spans founding, investing in, and advising startups, as well as serving in senior leadership roles. He has earned multiple industry awards and is passionate about sharing his knowledge, teaching entrepreneurship to high school students in his free time.
In addition to his professional achievements, Maxim is a certified Rescue Diver and a competitive race driver, exemplifying his drive for excellence both in and out of the workplace.